Interestingly, we found that in IDH-wild-type glioma patients, high MGMT expression indicates worse survival (P = 0.02, log-rank test, Supplementary Fig. 1e), while it is associated to a trend of better survival in IDH-mutant patients (P = 0.04, log-rank test, Supplementary Fig. 1f). Here, IDH2 is linked to central nervous system cancer.